Non-Vitamin K Antagonist Oral Anticoagulants in Adult Congenital Heart Disease.

Mongeon, François-Pierre; Macle, Laurent; Beauchesne, Luc M; Bouma, Berto J; Schwerzmann, Markus; Mulder, Barbara J M; Khairy, Paul (2019). Non-Vitamin K Antagonist Oral Anticoagulants in Adult Congenital Heart Disease. Canadian journal of cardiology, 35(12), pp. 1686-1697. Elsevier 10.1016/j.cjca.2019.06.022

[img] Text
1-s2.0-S0828282X1930443X-main.pdf - Accepted Version
Restricted to registered users only until 27 June 2020.
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy
[img] Text
1-s2.0-S0828282X1930443X-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (608kB) | Request a copy

Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have several advantages over VKAs that render them an attractive option for adults with congenital heart disease (CHD). Efficacy and safety data specific to the adult CHD population are emerging. Herein, we synthesize the growing literature regarding NOACs in adults with CHD and attempt to identify subgroups for which it appears reasonable to extrapolate data from populations without CHD. Small observational studies suggest that NOACs are safe and effective in selected adults with CHD. NOACs are contraindicated in patients with a mechanical valve, in those with mitral or tricuspid valve stenosis with enlarged and diseased atria, with or without a mitral or tricuspid bioprosthesis, and after recent cardiac surgery (< 3 months). There is currently insufficient evidence to recommend NOACs in patients with a Fontan circulation or cyanotic CHD. Growing literature supports the use of NOACs in patients without CHD who have various forms of valvular heart disease. Therefore, when an indication for oral anticoagulation is established, it appears reasonable to consider a NOAC instead of a VKA in adults with CHD lesions analogous to isolated mitral regurgitation, tricuspid regurgitation, or aortic regurgitation or stenosis. The NOAC agent selected and the prescribed dose should be tailored according to bleeding risk, body weight, renal function, and comedications, especially antiepileptic drugs. The decision to initiate a NOAC should be shared between the patient and care provider. Large-scale research studies are required to further assess safety and efficacy in selected patient subgroups.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Schwerzmann, Markus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0828-282X

Publisher:

Elsevier

Language:

English

Submitter:

Markus Schwerzmann

Date Deposited:

05 Dec 2019 12:51

Last Modified:

11 Dec 2019 01:33

Publisher DOI:

10.1016/j.cjca.2019.06.022

PubMed ID:

31635950

BORIS DOI:

10.7892/boris.135684

URI:

https://boris.unibe.ch/id/eprint/135684

Actions (login required)

Edit item Edit item
Provide Feedback